The US has provided doses of an experimental antibody drug from Mapp Biopharmaceutical for use in clinical trials to fight the widening Ebola outbreak in Democratic Republic of Congo, a Health Department spokesperson said, a shift from its position of making the drug available just for Americans.
After dismantling the US Agency for International Development and slashing aid to the region, the US is now making modest contributions to assist with what the US Centers for Disease Control and Prevention has said could potentially be the worst Ebola outbreak yet without a strong response.
The Department of Health and Human Services spokesperson declined to comment on the number of doses it will provide, saying by email that the drug is being made available for compassionate use in Congo as well as to advance a clinical trial in the outbreak region.
Also Read
Stakeholders back mining revenue retention strategy
